Recently merged CROs Accelovance and Linical rebrand, name new CEO

02-Aug-2018 - Last updated on 02-Aug-2018 at 14:45 GMT

(Image: Getty/tomertu)

Accelovance and Linical merged in March of this year to create a global midsized CRO for which ‘future possibilities are endless,’ says newly appointed CEO.

The firms merged with the goal to create a midsized global contract research organization (CRO) in response to the need for large-scale multinational clinical trials.

Now, the companies have announced that the CRO will operate as Linical Accelovance Group moving forward, led by its new CEO, Vita M. Lanoce, MS. Lanoce was previously the chief operating officer of Accelovance, and has worked at other companies including Covance, Synexus, and Bristol-Myers Squibb.

“I look forward to capitalizing on the talented staff of the Linical Accelovance Group, the extended geographical reach, efficiency of operations and broadening of services the merger has provided,” she told us.

According to Lanoce, pharma and biotech sponsors come to the CRO seeking “personal service, flexibility, operational, scientific and medical expertise, and innovative solutions they are not able to get from the mega CROs.”

“Our clients appreciate the personal, hands-on approach of our operations team along with the knowledge that each study will have an executive sponsor to support them, whether the study is a single POC study or a large multi-study clinical development program,” she added.

Lanoce said the company plans to continue focusing on early oncology research, while expanding its solutions into additional therapeutic areas.

“The future possibilities for this organization are endless,” she said, “including the potential for additional expansion in North and South America as well as Australia, while continuing to enhance our reach in China and APAC.”